Systemic lipopolysaccharide recruits dendritic cell progenitors to nonlymphoid tissues.
Dendritic cells (DC) are thought to be the "passenger leukocytes" that sensitize the recipients of organ transplants against graft antigens and trigger allograft rejection. DC originate from MHC class II-negative (Ia-) progenitors in the bone marrow, which enter the tissues and develop into migratory cells with the specialized capacity to initiate primary immune responses. There is little information on which stimuli recruit DC progenitors to the tissues. Systemic administration of LPS to mice depletes Ia+ leukocytes from heart and kidney but recruits Ia- leukocytes (Roake JA, et al., see footnote 6). When these leukocytes were isolated and cultured overnight, Ia+ low density leukocytes developed that could stimulate primary T cell responses in vitro. Hearts from LPS-treated mice were transplanted to allogeneic recipients. One to 4 days after grafting, Ia+ donor cells were present in recipient spleens, localized to peripheral white pulp, and associated with CD4+, but not CD8+, T cells. Cells with the migratory characteristics of DC, therefore, originated from Ia- progenitors in the transplanted hearts. We conclude that LPS recruits Ia- DC precursors to the heart and kidneys. Hearts from LPS-treated donors were rejected by allogeneic recipients at the same tempo as normal hearts, implying that Ia- DC progenitors might ultimately contribute to heart graft rejection (direct sensitization). However, since hearts from cyclophosphamide-treated donors, which do not give rise to Ia+ cells in recipient spleens, were also rejected at a similar tempo, indirect sensitization could also play a role in heart graft rejection in this model.
Roake
J A
JA
Nuffield Department of Surgery, University of Oxford, John Radcliffe Hospital, Headington, United Kingdom.
Rao
A S
AS
Morris
P J
PJ
Larsen
C P
CP
Hankins
D F
DF
Austyn
J M
JM
D000818:Animals; D017951:Antigen Presentation; D002465:Cell Movement; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000166:cytology / Q000187:drug effects* / Q000276:immunology; D016027:Heart Transplantation / Q000276:immunology*; D000949:Histocompatibility Antigens Class II / Q000096:biosynthesis; D007668:Kidney / Q000166:cytology / Q000276:immunology; D008070:Lipopolysaccharides / Q000008:administration & dosage*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D009206:Myocardium / Q000166:cytology / Q000276:immunology; D013234:Stem Cells / Q000166:cytology; D014184:Transplantation, Homologous
D000949:Histocompatibility Antigens Class II; D008070:Lipopolysaccharides